-
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Paschen-Wolff M, Greenfield SF, McHugh RK, Burlew AK, Pavlicova M, Choo T, Barbosa-Leiker C, Ruglass LM, Mennenga S, Rotrosen J, Nunes EV, Campbell ANC. Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder. American Journal on Addiction 2023;32(6):584-592.
-
Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder.
Shulman M, Choo T, Scodes J, Pavlicova M, Novo P, Campbell ANC, Greiner M, Lee JD, Rotrosen J, Nunes EV. Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder. Journal of Addiction Medicine 2023;17(5):618-620.
-
Nonparametric causal mediation analysis for stochastic interventional (in)direct effects.
Hejazi NS, Rudolph KE, Van Der Laan MJ, Díaz I. Nonparametric causal mediation analysis for stochastic interventional (in)direct effects. Biostatistics 2023;24(3):686-707.
-
Towards shortening the Brief Addiction Monitor-Revised (BAM-R).
Blanchard BE, Lynch KG, Malte CA, Hawkins EJ, DePhillippis D, Oslin DW, McKay JR, Saxon AJ. Towards shortening the Brief Addiction Monitor-Revised (BAM-R). Drug and Alcohol Dependence Reports 2023;8:100183.
-
What to expect with pregnant or postpartum prescribing of extended-release buprenorphine (CAM2038).
Lofwall MR, Young JL, Hansen Z, Wachman EM, Wilder C, Guille C, Charles JE, Leeman L, Gray JR, Winhusen TJ. What to expect with pregnant or postpartum prescribing of extended-release buprenorphine (CAM2038). Journal of Clinical Gynecology and Obstetrics 2023;12(3):110-116.
-
Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design.
Roy PJ, Kim KC, Suda K, Luo J, Wang X, Olejniczak D, Liebschutz JM. Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design. Drug and Alcohol Dependence Reports 2023;6:10035.
-
High suicidality predicts overdose events among people with substance use disorder: A latent class analysis.
Schmidt RD, Horigian VE, Shmueli-Blumberg D, Hefner K, Feinberg J, Kondapaka R, Feaster DJ, Duan R, Gonzalez S, Davis C, Vena A, Marin-Navarette R, Tross S. High suicidality predicts overdose events among people with substance use disorder: A latent class analysis. Frontiers in Public Health 2023;11:1150062.
-
The potential impact of clinical decision support on nonwaivered primary care clinicians’ prescribing of buprenorphine.
Olson AW, Haapala JL, Hooker SA, Solberg LI, Bogert-Spaniol CM, Romagnoli KM, Allen CI, Tusing LD, Wright EA, Haller IV, Rossom RC. The potential impact of clinical decision support on nonwaivered primary care clinicians' prescribing of buprenorphine. Health Affairs Scholar 2023;1(4):qxad051.
-
A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians.
Hooker SA, Crain AL, LaFrance AM, Kane S, Fokuo JK, Bart G, Rossom RC. A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians. Addiction Science & Clinical Practice 2023;18:10.
-
Overall and telehealth addiction treatment utilization by age, race, ethnicity, and socioeconomic status in California after COVID-19 policy changes.
Palzes VA, Chi FW, Metz VE, Sterling S, Asyyed A, Ridout KK, Campbell CI. Overall and telehealth addiction treatment utilization by age, race, ethnicity, and socioeconomic status in California after COVID-19 policy changes. JAMA Health Forum 2023;4(5):e231018.